Safety study of RO7663498 eye injection for diabetic retinopathy
Part of Eyes & vision, Heart & circulation, Hormones & metabolism clinical trials.
This is an early-stage safety study testing a new medicine injected directly into the eye to treat diabetic retinopathy (damage to blood vessels in the retina caused by diabetes). The study checks if the medicine is safe and how the body processes it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have Type 1 or Type 2 diabetes
- Your vision in the study eye is at least 19 letters on a standard eye chart
- You have non-proliferative diabetic retinopathy (early-stage vessel damage in the retina, not the most advanced form)
- You don't have swelling in the center of your retina (diabetic macular edema)
- You've never had retinal surgery or glaucoma surgery in the study eye
- No recent eye inflammation or active eye infections
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a new medicine (MK-8748) works as well as or better than the usual treatment (aflibercept) for people with diabetic macular edema, a condition that causes vision loss from diabetes-related swelling in the back of the eye.
This study tests an investigational drug called BI 764524 for people with moderate to severe diabetic retinopathy, a complication of diabetes that can damage the retina. The goal is to see if the treatment can help prevent vision loss.
This study tests whether an experimental eye drop can slow or treat early-stage diabetic retinopathy. If you have diabetes-related vision changes, this treatment might help prevent the condition from getting worse.
This study tests a new approach aimed at improving diabetic eye disease (diabetic retinopathy). It may help by changing inflammation and related processes in the eye, especially in people who have diabetes and eye changes.
This early-phase study tests a treatment aimed at preventing or slowing early diabetic eye disease in people with mild, early changes. You may be considered if your diabetes is moderately controlled and your eye tests show early warning signs.
This early safety study tests how well and how safely an investigational dye (MB-102) works during a special eye imaging test of retinal and choroidal blood vessels. It compares it to the commonly used fluorescein dye and may help doctors refine future eye imaging approaches.
Hear when a new Diabetic Retinopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.